Opthea (OPT) Competitors $3.41 0.00 (0.00%) As of 07/11/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OPT vs. AGIO, CGON, KNSA, BEAM, IDYA, IRON, BLTE, CNTA, HRMY, and ADPTShould you be buying Opthea stock or one of its competitors? The main competitors of Opthea include Agios Pharmaceuticals (AGIO), CG Oncology (CGON), Kiniksa Pharmaceuticals International (KNSA), Beam Therapeutics (BEAM), IDEAYA Biosciences (IDYA), Disc Medicine (IRON), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), Harmony Biosciences (HRMY), and Adaptive Biotechnologies (ADPT). These companies are all part of the "pharmaceutical products" industry. Opthea vs. Its Competitors Agios Pharmaceuticals CG Oncology Kiniksa Pharmaceuticals International Beam Therapeutics IDEAYA Biosciences Disc Medicine Belite Bio Centessa Pharmaceuticals Harmony Biosciences Adaptive Biotechnologies Opthea (NASDAQ:OPT) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability. Is OPT or AGIO more profitable? Agios Pharmaceuticals has a net margin of 1,798.26% compared to Opthea's net margin of 0.00%. Opthea's return on equity of 0.00% beat Agios Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets OptheaN/A N/A N/A Agios Pharmaceuticals 1,798.26%-2.75%-2.52% Do institutionals & insiders hold more shares of OPT or AGIO? 56.0% of Opthea shares are held by institutional investors. 3.2% of Opthea shares are held by company insiders. Comparatively, 4.3% of Agios Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better earnings & valuation, OPT or AGIO? Agios Pharmaceuticals has higher revenue and earnings than Opthea. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpthea$120K4,373.61-$220.24MN/AN/AAgios Pharmaceuticals$36.50M61.97$673.72M$11.243.47 Which has more risk & volatility, OPT or AGIO? Opthea has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Do analysts prefer OPT or AGIO? Opthea currently has a consensus target price of $1.33, suggesting a potential downside of 60.90%. Agios Pharmaceuticals has a consensus target price of $58.60, suggesting a potential upside of 50.06%. Given Agios Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Agios Pharmaceuticals is more favorable than Opthea.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opthea 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.17Agios Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Does the media refer more to OPT or AGIO? In the previous week, Agios Pharmaceuticals had 6 more articles in the media than Opthea. MarketBeat recorded 7 mentions for Agios Pharmaceuticals and 1 mentions for Opthea. Opthea's average media sentiment score of 0.93 beat Agios Pharmaceuticals' score of 0.88 indicating that Opthea is being referred to more favorably in the media. Company Overall Sentiment Opthea Positive Agios Pharmaceuticals Positive SummaryAgios Pharmaceuticals beats Opthea on 8 of the 15 factors compared between the two stocks. Get Opthea News Delivered to You Automatically Sign up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPT vs. The Competition Export to ExcelMetricOptheaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$524.83M$2.97B$5.62B$9.10BDividend YieldN/A2.39%5.24%4.00%P/E RatioN/A20.7128.1020.27Price / Sales4,373.61292.05429.7098.72Price / CashN/A42.8637.4658.16Price / Book-6.097.638.045.49Net Income-$220.24M-$55.05M$3.18B$250.45M7 Day PerformanceN/A8.43%3.62%4.78%1 Month PerformanceN/A5.42%4.05%7.67%1 Year Performance69.65%2.03%30.00%16.43% Opthea Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPTOpthea0.273 of 5 stars$3.41flat$1.33-60.9%+72.2%$524.83M$120K0.008Gap UpAGIOAgios Pharmaceuticals4.3881 of 5 stars$35.21-2.4%$58.60+66.4%-12.0%$2.09B$36.50M3.13390Insider TradeAnalyst RevisionCGONCG Oncology2.4267 of 5 stars$26.25-2.4%$58.67+123.5%-22.5%$2.05B$1.14M-17.3861Positive NewsAnalyst UpgradeKNSAKiniksa Pharmaceuticals International3.5477 of 5 stars$27.95+0.3%$38.80+38.8%+30.0%$2.03B$423.24M-111.80220Analyst ForecastBEAMBeam Therapeutics2.3033 of 5 stars$19.18-4.1%$48.75+154.2%-18.2%$2.01B$63.52M-4.16510News CoverageIDYAIDEAYA Biosciences3.6232 of 5 stars$21.16-4.3%$53.73+153.9%-43.3%$1.94B$7M-5.8980News CoverageAnalyst UpgradeIRONDisc Medicine3.2354 of 5 stars$53.38-2.5%$96.70+81.2%+21.3%$1.90BN/A-13.6230Insider TradeBLTEBelite Bio2.3688 of 5 stars$58.63-1.4%$96.67+64.9%+29.2%$1.89BN/A-43.1110News CoverageAnalyst RevisionCNTACentessa Pharmaceuticals3.2635 of 5 stars$13.62-3.2%$27.89+104.8%+50.8%$1.88B$6.85M-7.52200HRMYHarmony Biosciences4.8653 of 5 stars$32.24+0.2%$53.63+66.3%+2.0%$1.85B$714.73M12.31200News CoveragePositive NewsAnalyst ForecastADPTAdaptive Biotechnologies2.8675 of 5 stars$11.74-0.5%$10.57-10.0%+203.9%$1.79B$178.96M-12.23790 Related Companies and Tools Related Companies AGIO Alternatives CGON Alternatives KNSA Alternatives BEAM Alternatives IDYA Alternatives IRON Alternatives BLTE Alternatives CNTA Alternatives HRMY Alternatives ADPT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPT) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Opthea With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
